It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Overall investment in the US facility is estimated around US$50 million
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Subscribe To Our Newsletter & Stay Updated
